Wei R. Chen, PhD
Dr. Wei R. Chen is a Professor in the Department of Engineering and Physics and the Assistant Dean of the College of Mathematics and Science at the University of Central Oklahoma, as well as an Adjunct Professor at the University of Oklahoma and the Oklahoma State University. Dr. Chen's research focuses on laser medicine, with a special emphasis on cancer treatment and immunotherapy. Dr. Chen is a Fellow of SPIE (International Society of Optical Engineering) and he established and chaired the international conference "Biophotonics and Immune Responses" since 2006. Dr. Chen was the recipient of 2008 US Professor of the Year award. Dr. Chen is the co-inventor of laser-assisted immunotherapy.
Mark F. Naylor, MD
Dr. Naylor received his medical degree from Texas Tech University School of Medicine in 1981 and his specialty certificate in internal medicine from the University of Alabama in 1984. Dr. Naylor completed his scientific fellowship in tumor biology at the MD Anderson Cancer Center in 1990 and joined the faculty at the University of Oklahoma School of Medicine Department of Dermatology. Dr. Naylor left University of Oklahoma in 2009 to join Dermatology Associates of San Antonio where he now applies his knowledge of photodamage and tumor biology to skin cancer therapy. In his capacity as a tumor biologist, Dr. Naylor has been very active in the American Academy of Dermatology, helping set standards for cancer treatment and prevention.
Robert E. Nordquist, PhD
Dr. Nordquist received a BA in psychology at Oklahoma City University in 1968 and a PhD from the University of Oklahoma in 1971. He did postgraduate training at the National Cancer Institute in Molecular Virology, and also at the Scripps Institute in La Jolla California in the Experimental Immunology Department. Nordquist served in academic, teaching and research positions on the University of Oklahoma health sciences Center campus for more than 40 years. During his tenure he was the founding president of the Oklahoma microscopy Society and was appointed as the first Snetcher endowed chair of research ophthalmology. Nordquist has been president of Wound healing of Oklahoma Inc. for more than 15 years. His interests are pathology, cancer, immunology and cell biology. Dr. Nordquist is the main inventor of laser-assisted immunotherapy.
Michael R. Hamblin, PhD
Dr. Hamblin is a Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and an Associate Professor at Harvard Medical School. Dr. Hamblin's primary research interests are broadly in the area of phototherapy for multiple diseases, including the study of new photosensitizers for infections, cancer, and heart disease. He has published over 95 peer-reviewed articles, over 100 conference proceedings, book chapters and International abstracts, and he has edited the most recent and comprehensive textbook on PDT entitled "Advances in Photodynamic Therapy: Basic, Translational and Clinical".
Maria Guerra, MD
Dr. Guerra is an oncologist with a long experience of clinical practice and cancer medicine. She was an attending physician for over twenty years at Internal Medicine and Hematology-Oncology at Kaiser Permanente in California. Dr. Guerra oversees human breast cancer trials on behalf of Immunophotonics.
John Weatherspoon, PhD, JD
Dr. Weatherspoon, of Stein McEwen LLP, received a B.S. in Neuroscience from Duke University and a Ph.D. in Pharmacology from The George Washington University. He received his J.D from the George Mason University School of Law where he focused on Intellectual Property Law. Prior to his legal career, Dr. Weatherspoon spent several years engaged in biotechnology and pharmaceutical research at the Duke University Medical Center, the Radiobiology Research Institute, an institute of the Department of Defense, and the Pharmacology Division of Burroughs Wellcome Company, now part of GlaxoSmithKline. Furthermore, Dr. Weatherspoon is admitted to practice law in Maryland and was a Biotechnology Patent Examiner at the U.S. Patent and Trademark Office. Dr. Weatherspoon has extensive experience with patent preparation and prosecution. In particular, his experience includes drafting and prosecuting numerous patent applications in the chemical, biotechnological, and pharmaceutical arts.
Richard Levenson, MD, FCAP
Dr. Levenson received his undergraduate degree in History and Literature at Harvard College, his medical degree at the University of Michigan and his pathology training at Washington University, St. Louis. Following a research fellowship at the University of Rochester, he accepted a faculty position in the pathology department at Duke University. He then moved to Carnegie Mellon University where he began to develop applications in biology and medicine for multispectral imagining. In 1999, he joined Cambridge Research and Instrumentation (CRI), where he rose to become Vice President of Research. While at CRI, he was Principal Investigator on multiple NIH-funded grants, whose projects included the development of automated, multiplexed pathology instrumentation, three-dimensional multispectral small-animal imaging systems, optical dynamic contrast enhancement technique, and high-speed birefringence optical microscopy. Total funding achieved during his 10 years at CRI amounted to over $16M. He has been a long-time reviewer on NIH and NCI grant review study sections, is Associate Editor of Analytical Cell Pathology and serves on the editorial boards of Laboratory Investigation and Cytomertry Part A.
Paul Dale, MD
Dr. Dale is both a Professor of Clinical Surgery and Chief of the Division of Surgical Oncology at the University of Missouri–Columbia’s Ellis Fischel Cancer Center. He was awarded his medical doctorate in 1988 from the University of Alabama School of Medicine, and he completed an internship and residency in general surgery at Mercer University School of Medicine in Georgia. He went on to complete a fellowship in surgical oncology at the John Wayne Cancer Institute in California. Before coming to Missouri, Dr. Dale was a private practice physician in Georgia and also held several academic appointments there. In addition to participating in several research programs and on committees both within the hospital and statewide, Dr. Dale holds the academic honor of being the Margaret Proctor Mulligan Professor in Breast Cancer Research at the University of Missouri School of Medicine. His special interests include breast cancer and surgery, cancer prevention and screening, colon cancer and surgery, esophageal cancer and surgery, liver surgery, musculoskeletal oncology, pancreatic cancer and surgery, rectal cancer, skin cancer and surgery, stomach cancer, and surgical oncology. He publishes and presents widely on these and other topics.
Jake Halliday, PhD
Dr. Halliday is President & CEO of the Missouri Innovation Center which assists technology entrepreneurs with opportunity assessment, R&D planning, new venture creation, and securing capital through private equity investment and SBIR/STTR grants. Dr Halliday led the initiative to fund and build the Life Science Business Incubator in Columbia Missouri which he now leads as its CEO. He is the deal facilitator for Centennial Investors angel network and serves on the board of that organization. Dr Halliday is also a faculty member at the Trulaske College of Business where he teaches an MBA course that simulates planning and securing funding for high-tech startups. Dr Halliday has 21 years experience in biomedical product development, including 11 years as CEO of a mid-size CRO. He was appointed by Ronald Reagan to the Presidential Agricultural Task Force to Zaire, and by Secretary Brown to the Board on Science and Technology Cooperation between the United States and N. Ireland. He served for four years on the Board on Science and Technology in International Development of the National Academy of Sciences. Dr Halliday was a founding director of the Maui Economic Development Board and is currently a Director and Board Member of several early stage technology companies. Dr Halliday’s PhD is from the University of Western Australia and his BSc is from Queen’s University, Belfast (N. Ireland).
Orn Adalsteinsson, PhD
Dr. Adalsteinsson has held several executive positions in the life science industry during his 25-year career. Prior to forming the International Strategic Cancer Alliance, which are working closely with Immunophotonics, he was the head of New Business Development at Arkion Life Sciences LLC, a privately held company focusing on human health and animal feed products that was formed following DCV Inc, a joint venture of DuPont and ConAgra. As President of DCV Biologics LP, one of the predecessor companies of Arkion, Dr. Adalsteinsson developed and marketed nutraceutical technologies worldwide. Dr. Adalsteinsson has held numerous managerial positions during his tenure at DuPont and Procter and Gamble. Dr. Adalsteinsson holds a Ph.D. and M.Sc. in Chemical Engineering from the Massachusetts Institute of Technology. His primary areas of research have covered protein chemistry, nutraceuticals, enzyme kinetics, enzyme reactor designs, pharmacokinetics, fluid dynamics, heat and mass transfer. He has authored many articles published in technical journals in the field of protein chemistry and holds several patents.